
Novo Nordisk (NVO) has multiple positive catalysts on the horzon, including its recent decision to offer subscriptions to Wegovy, its popular GLP-1 weight-loss drug. Still, given a forthcoming — and potentially huge — negative catalyst facing the company, investors may want to refrain from buying NVO stock for now.
What's going on with Novo Nordisk? Let's take a closer look.